Clinical Trial Search

Primary: The Number of Device and/or Procedure-Related Adverse Events — 12 device or procedure-related AEs

Primary: Percentage of Correctly Identified Pre-treatment Photos by a Panel of Blinded Independent Reviewers — 16; 15 photos

Primary: Proportion of Pre-treatment Images Correctly Identified — 32 photos

Primary: The Number of Participants With Grade 1 or Higher ("Improved, Much Improved, Very Much Improved") in Investigator-assessed Global Aesthetic Improvement Scale (GAIS) at…

Primary: Renal Video Intensity Units — 19 units on a scale

Primary: % of Photos Identified Correctly When Comparing 12 Week Follow Up to Baseline — 57 % of photos identified correctly

Primary: Number of Treatment Samples With Different Levels of Elastin When Compared to Baseline Samples From the Same Patient — 0 biopsy samples

Primary: Seroma Formation — 54.27; 59.56; 102.21; 117.94 ml — p=<0.005

Primary: The Amount of Opioid Consumption During and After Procedure — 26.3; 27.1; 5.49; 5.52 mg IV morphine equivalents

Primary: Change in the Percentage of Fat Thickness From Baseline to 12-weeks Post-treatment — -6.9 percentage of body fat

Primary: Safety of the Zeltiq System for Non-invasive Fat Reduction in Subjects With Greater Flank Curvature. — 0; 0 UADEs

Primary: Number of Participants With Treatment-related Adverse Events [AEs] — 12; 12; 9; 12 participants

Primary: Post-operative Pain Severity Assessed by VAS at Hour-4 — 1.4; 2.2 score on a scale

Primary: Number of Participants Who Had at Least One Grade Improvement on the Submental Skin Laxity Scale — 2 Participants

Primary: Number of Participants With a Reduction of Submental Skin Area ≥ 20 mm^2 — 49 Participants

Primary: General Improvement in Skin Laxity of the Flank Area — 1.1; 2.1 units on a scale — p=<0.01

Primary: Score on Visual Analog Scale (VAS) - 1 Hour Post-intervention — 6.64; 6.67; 4.62; 6.93 score on a scale

Primary: Stone Clearance — 76 participants

Primary: Opioid Consumption in Oral Morphine Milliequivalents for the First 24 Hours After Surgery (Defined as 24 Hours After the Anesthesia End Time) — 17.50; 21.25 oral…

Primary: Correlation Between Prone Breast MRI for Estimation of Tumor Size and Final Pathology Tumor Size — 0.635 correlation coefficient

Primary: Achievement of ≥ 2-Grade Improvement From Baseline on the Masseter Muscle Prominence Scale (MMPS) at Day 90 — 2.2; 51.2 percentage of participants — p=<0.0001

Primary: Opioid Consumption — 113.5; 147 milligrams oral morphine equivalent

Primary: Number of Participants With Presence of Fluorescence of cT1 RCC in Partial Nephrectomy Specimens — 10 Participants

Primary: Number of Successful Segmentation of Supine MRI Images — 54; 61 Participants

Primary: Average Pain Score — 5.2; 5.1 score on a scale — p=.883

Primary: Successful Capture of IO-CEUS Images — 10 participants

Primary: Size Error in Millimeters — 0 milimeters

Primary: Participants Who Received a Second Parenteral Pain Medication in the Emergency Department (ED) — 0 Participants

Primary: Skin Temperature Increase From Baseline — 1.9; 2.3 degrees C

Primary: Number of Participants Assessed for Donor Site Complications and Muscle Flap Viability — 15 Participants